TDSPHARM Co., Ltd. Logo

TDSPHARM Co., Ltd.

Develops and manufactures transdermal drug delivery systems like patches, plasters, and OTC products.

464280 | KO

Overview

Corporate Details

ISIN(s):
KR7464280007
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로 253 C동 403호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TDSPHARM Co., Ltd. is a pharmaceutical company specializing in the research, development, and manufacturing of Transdermal Drug Delivery Systems (TDDS). Founded in 2002, the company leverages its expertise in TDDS technology to produce a range of products, including medical cataplasmas, plasters, and patches. Its portfolio also encompasses over-the-counter (OTC) medicines and cosmetic products. The company is committed to R&D to deliver safe and efficient medicinal products that are absorbed through the skin, with a goal of providing accessible healthcare solutions to consumers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 86.7 KB
2025-09-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 814.7 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 783.5 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-05-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 89.0 KB
2025-04-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.5 KB
2025-04-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 90.5 KB
2025-04-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 19.6 KB
2025-03-17 00:00
Audit Report / Information
감사보고서제출
Korean 18.0 KB
2025-03-17 00:00
Annual Report
사업보고서 (2024.12)
Korean 437.1 KB
2025-03-17 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1013.2 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 101.9 KB
2025-02-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.1 KB

Automate Your Workflow. Get a real-time feed of all TDSPHARM Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TDSPHARM Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TDSPHARM Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.